# Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant

> **NCT00110045** · PHASE2 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 171 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** caspofungin acetate

## Key facts

- **NCT ID:** NCT00110045
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2008-03
- **Final completion:** —
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2012-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00110045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00110045, "Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00110045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*